FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
April 25, 2024 08:00 ET
|
Fibrobiologics, Inc.
HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug...
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
April 11, 2024 09:31 ET
|
Fibrobiologics, Inc.
HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
April 04, 2024 09:31 ET
|
Fibrobiologics, Inc.
HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development...
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
March 28, 2024 09:31 ET
|
Fibrobiologics, Inc.
HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...